28 completed. 28 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 28 | Completed 28 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt Sofosbuvir 400 MG/ Daclatasvir 60mg - Covid19 | Phase 4 | Completed | Alexandria University | 54 | 2020-11-01 | 2021-02-26 |
| The Kentucky Viral Hepatitis Treatment Study Sofosbuvir/velpatasvir (Epclusa®) - Hepatitis C, Opioid-Related Disorders | Phase 4 | Completed | Jennifer Havens | 380 | 2019-09-23 | 2026-10-20 |
| DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Sofosbuvir 400 mg and Daclatasvir 60 mg, Sofosbuvir 400 mg and Daclatasvir 90 mg, Ribavirin - Hepatitis C, Drug Use | Phase 4 | Completed | ANRS, Emerging Infectious Diseases | 979 | 2018-11-13 | 2023-10-26 |
| Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy - Hepatitis C, HIV-1-infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 400 | 2018-10-22 | 2022-02-04 |
| Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] - Beta-Thalassemia, Hepatitis C | Phase 4 | Completed | Tanta University | 50 | 2017-10-01 | 2019-05-23 |
| Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir Sofosbuvir 400 mg and daclatasvir 60 mg - Hepatitis C, Chronic, Chronic Renal Failure | Phase 4 | Completed | Tehran University of Medical Sciences | 95 | 2017-04-01 | 2019-09-30 |
| deLIVER: Direct Acting Antiviral Effects on the Liver Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL) - HCV Coinfection, Liver Disease | Phase 4 | Completed | Johns Hopkins University | 15 | 2017-01-01 | 2022-02-24 |
| Hepatitis C Virus(HCV) Heart and Lung Study Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) - Hepatitis C, Chronic, Heart Failure | Phase 4 | Completed | Duke University | 15 | 2016-12-01 | 2020-04-21 |
| Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Harvoni (Fixed dose combination ledipasvir/sofosbuvir) - Hepatitis C | Phase 4 | Completed | Rockefeller University | 34 | 2016-11-15 | 2019-08-13 |
| Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients sofosbuvir and daclatasvir - Hepatitis C | Phase 4 | Completed | Tehran University of Medical Sciences | 1448 | 2016-09-01 | 2019-02-15 |
| Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Zepatier, Ribavirin, Sofosbuvir - End-Stage Renal Disease, Hepatitis C | Phase 4 | Completed | Johns Hopkins University | 10 | 2016-07-20 | 2018-09-06 |
| LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks - Hepatitis C | Phase 4 | Completed | Medical University of South Carolina | 32 | 2016-06-01 | 2019-05-07 |
| Study of Oral Treatments for Hepatitis C SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir) - Chronic Hepatitis C | Phase 4 | Completed | University of Florida | 1275 | 2016-06-01 | 2021-12-06 |
| Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon Sofosbuvir - Hepatitis C, Chronic | Phase 4 | Completed | PharmEvo Pvt Ltd | 573 | 2016-06-01 | 2018-09-17 |
| Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) sofosbuvir, ledipasvir - Hepatitis C | Phase 4 | Completed | Instituto de Investigación Marqués de Valdecilla | 64 | 2016-05-10 | 2017-05-18 |
| Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Daclatasvir + Sofosbuvir, Simeprevir + Sofosbuvir - Hepatitis C, Chronic | Phase 4 | Completed | Federal University of São Paulo | 121 | 2015-12-01 | 2017-08-01 |
| Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia Ledipasvir 90 mg and Sofosbuvir 400 mg - HCV HIV | Phase 4 | Completed | National Institutes of Health Clinical Center (CC) | 600 | 2015-01-07 | 2018-08-14 |
| Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients SOF+RBV, SOF+DCV, LDV/SOF - Chronic Hepatitis C Infection | Phase 4 | Completed | Humanity and Health Research Centre | 112 | 2015-01-01 | 2018-03-19 |
| Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks - Liver Cirrhosis | Phase 4 | Completed | Azienda Ospedaliera San Camillo Forlanini | 270 | 2015-01-01 | 2016-03-09 |
Showing 20 of 28. Sign in to see all of them.
Hepatitis C (18) · Hepatitis C, Chronic (7) · Fibrosis (2) · Kidney Failure, Chronic (2) · Liver Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · HIV Infections (1) · Heart Failure (1) · Hepatitis B (1) · Liver Cirrhosis (1) · Lung Diseases, Interstitial (1) · Opioid-Related Disorders (1) · Pulmonary Disease, Chronic Obstructive (1)
Humanity and Health Research Centre (2) · Johns Hopkins University (2) · Tanta University (2) · Tehran University of Medical Sciences (2) · ANRS, Emerging Infectious Diseases (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Alexandria University (1) · Azienda Ospedaliera San Camillo Forlanini (1) · Center For Hepatitis C, Atlanta, GA (1) · Duke University (1) · Federal University of São Paulo (1) · Gilead Sciences (1) · Helwan University (1) · Instituto de Investigación Marqués de Valdecilla (1) · Jennifer Havens (1)
United States (14) · Egypt (4) · Brazil (2) · China (2) · Iran (2) · Australia (1) · Italy (1) · New Zealand (1) · Pakistan (1) · Puerto Rico (1) · South Africa (1) · Spain (1) · Thailand (1) · Uganda (1) · Vietnam (1)
Adriano M Pellicelli, MD (1) · Andrew Muir, MD (1) · Asem Elfert, Prof (1) · Brian L Pearlman, MD (1) · Carmen Cobo Pelayo, MD (1) · David R Nelson, MD (1) · Eslam Esmail, Ass Lecturer (1) · Gail Matthews, MbChB FRACP (1) · George KK Lau, MD (1) · George Lau, MD (1) · Guofeng Chen, MD (1) · Hala M Elsabagh, Prof (1) · Henry Masur, M.D. (1)
PMID 24067879, PMID 24209977, PMID 24720702, PMID 24997638, PMID 25557952, PMID 26890629, PMID 27237429, PMID 27782373, PMID 28785771, PMID 29507971, PMID 29535545, PMID 29906601, PMID 31504303, PMID 31994788, PMID 32356185, PMID 33208326, PMID 34226208, PMID 34255381, PMID 35026142, PMID 35182741, PMID 35657133, PMID 36694361, PMID 36722133, PMID 37088312, PMID 39656808, PMID 39702964, PMID 40019678, PMID 41017776, PMID 42852927
R01DA033777 (1), R01DA047952 (1), UM1AI068636 (1)